Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality
Open Access
- 26 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (10) , 2317-2324
Abstract
The functions of mast cells in human graft-versus-host disease (GVHD) are unknown. We studied 56 patients who had an allogeneic hematopoietic cell transplantation (alloHCT) with a biopsy for diagnosis of gastrointestinal tract (GIT) GVHD before any treatment (including steroids): 35 with GIT GVHD, 21 HCT recipients whose biopsies did not confirm GVHD, and 9 with a new diagnosis of inflammatory bowel disease (IBD) as a comparison. The median number of mast cells (mean of CD117+ cells, counted in 3 selected spots under 40× magnification) was similar between patients with GVHD (59 cells) and those without GVHD (60 cells). However, the median number of mast cells was significantly associated with maximum clinical stage of GIT GVHD; the lowest counts of mast cells were observed in the highest clinical stage of GIT GVHD (stage 1, 80; stage 2, 69; stage 3, 54; stage 4, 26; P = .01). Moreover, every decrease by 10 mast cells was associated with increased nonrelapse mortality through 1 year (hazard ratio, 0.77; 95% confidence interval, 0.59-1.00; P = .05). AlloHCT recipients all had significantly fewer mast cells, even those without GVHD compared with those with IBD (median, 59 vs 119; P < .01). The median number of GIT mast cells was also significantly lower in patients who received myeloablative conditioning (61.5 cells) than in those who received reduced intensity conditioning (78 cells) in the entire study population (P = .02). We conclude that GIT mast cells are depleted in all alloHCT patients, more prominently in those receiving myeloablative conditioning and those with severe GIT GVHD. Our novel findings warrant further investigation into the biological effects of mast cells in GIT GVHD.Keywords
This publication has 51 references indexed in Scilit:
- The Role of Mast Cells in the Defence against PathogensPLOS Pathogens, 2012
- Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host diseaseJournal of Leukocyte Biology, 2012
- The two faces of mast cells in food allergy and allergic asthma: The possible concept of Yin YangBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptorsNature Communications, 2012
- Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Blood, 2011
- Essential role for mast cell tryptase in acute experimental colitisProceedings of the National Academy of Sciences, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic diseaseBlood, 2007
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel diseaseHistopathology, 1996